Amyloidosis

Published on 05/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2695 times

39

Amyloidosis

Amyloidosis encompasses a wide range of disorders, several of which have cutaneous manifestations. The common thread is the formation of extracellular deposits that are composed of a β-pleated sheet by x-ray crystallography. In general, amyloid deposits exhibit a red color with Congo red stain and demonstrate birefringence (apple green color) under polarized light. Precursor proteins of amyloid vary from keratin to immunoglobulin (Ig) light chains to gelsolin. If necessary, tandem mass spectrometry can be performed to characterize the specific protein.

In dermatology, the initial distinction is between amyloidosis that is systemic versus skin-limited (Fig. 39.1). The former is less common than the latter.

Systemic Amyloidosis

Primary systemic amyloidosis is due to a plasma cell dyscrasia, but most patients do not fulfill the criteria for multiple myeloma (e.g. >10% plasma cells in a bone marrow biopsy, osteolytic bone lesions, anemia, hypercalcemia); the precursor protein is almost always Ig light chains (AL; lambda > kappa) rather than Ig heavy chains (AH).

Firm skin-colored to pink to yellow-brown waxy papules or plaques occur most commonly on the face (Fig. 39.2); infiltration of the tongue can lead to macroglossia (Fig. 39.3), and occasionally there is diffuse waxy induration of the skin (sclerodermoid presentation); purpura due to trauma or pinching of the skin can also be seen and is due to the fragility of blood vessels surrounded by amyloid deposits (Fig. 39.4).

Secondary systemic amyloidosis develops in the setting of chronic inflammation, e.g. rheumatoid arthritis, tuberculosis, and in several auto-inflammatory disorders (see Chapter 3); the precursor protein is (apo) serum AA, which is produced by the liver; cutaneous lesions rarely occur.

Amyloid deposits can also lead to a restrictive cardiomyopathy and congestive heart failure as well as renal dysfunction, especially nephrotic syndrome (Fig. 39.5).

Histologically, cutaneous papules are composed of dermal deposits of amyloid while clinically uninvolved skin (abdominal fat) can show perivascular deposits of amyloid; serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) aid in identifying a gammopathy, but the serum free light-chain assay is the most sensitive test available and the presence of monoclonal free light chains is required to establish the diagnosis.

DDx: for facial papules, lipoid proteinosis, mucinoses, colloid milium, multiple adnexal tumors (see Fig. 91.15).

Rx: for primary systemic amyloidosis, it is similar to myeloma, e.g. dexamethasone, melphalan, bortezomib, lenalidomide, and hematopoietic stem cell transplant (HSCT) (for younger patients).

Localized Cutaneous Amyloidosis

The three major forms of primary localized cutaneous amyloidosis are macular, lichen, and nodular amyloidosis (see Fig. 39.1); an overlap of the first two forms is referred to as biphasic because these two entities exist on a spectrum.

Both macular and lichen amyloidosis are due to rubbing, scratching, or friction and have a rippled appearance as well as hyperpigmentation; the macular form favors the upper back of adults while the lichenoid form favors the extensor surfaces of the extremities, primarily the anterolateral shins, and has a palpable component (Figs. 39.6 and 39.7).

Both forms occur more commonly in individuals with skin phototypes III and IV; cutaneous amyloidosis of the upper back is seen in patients with Sipple syndrome (multiple endocrine neoplasia [MEN] type 2A), but with an onset during childhood.

Mutations in two genes which encode the oncostatin M receptor β (a component of the IL-31 receptor) or the α subunit of the IL-31 receptor have been detected in patients with familial primary cutaneous amyloidosis; of note, IL-31 plays a role in pruritus.

The precursor protein for both macular and lichen amyloidosis is keratin, presumably from nearby keratinocytes; deposits of amyloid in the upper dermis can be subtle, especially in the macular form, and stain positively with anti-keratin antibodies.

Nodular amyloidosis presents as one or more waxy skin-colored to pink-orange plaques or nodules, most commonly on the trunk or extremities (Fig. 39.8); the precursor protein is Ig light chains ± β2-microglobulin, thought to be produced by cutaneous infiltrates of plasma cells.

A minority of patients with nodular amyloidosis may develop systemic amyloidosis, so longitudinal evaluation is recommended.

Occasionally, deposits of amyloid are seen in cutaneous tumors, e.g. basal cell carcinomas, dermatofibromas, intradermal melanocytic nevi, as an inconsequential secondary phenomenon.

DDx: back – notalgia paresthetica, lichen simplex chronicus (LSC) with post-inflammatory hyperpigmentation; lower extremity – LSC, hypertrophic lichen planus, pretibial myxedema; nodular – cutaneous lesions of systemic amyloidosis, pretibial myxedema, cutaneous lymphoma.

Rx: difficult; can try topical antipruritics, e.g. pramoxine, topical or intralesional CS; physical coverings, e.g. zinc oxide-impregnated gauze (Unna boot) or hydrocolloid dressings, can lead to improvement but recurrences common when discontinued.

For further information see Ch. 47. From Dermatology, Third Edition.